|
|
Strategic Analysis of the Age-Related Macular Degeneration; Diabetic Retinopathy and Diabetic Edema MarketsPublished by: Frost & Sullivan Published: Aug. 3, 2004 Table of ContentsIntroduction Disease Etiology AMD Diabetic Retinopathy Diabetic Macular Edema Patient Forecasts AMD Diabetic Retinopathy Diabetic Edema Current Therapeutic Options Emerging Pipeline Therapies Strategic Product Analysis Visudyne SnET2-PDT Macugen Retaane Lucentis Squalamine Posurdex Combretastatin CA4P AdPEDF VEGF Trap Revenues Forecasts Assumptions and Methodology Forecast Analysis AMD Comprehensive Comparative Pipeline Analysis Lucentis versus Macugen Retaane versus Macugen Visudyne versus Macugen Age-Related Macular Degeneration In the News Decision Support Databases - Ophthalmologists - Retinal Specialists AbstractNeed to Prove Unique Benefits Challenging Wet AMD Therapeutics MarketWhile instances in age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic edema (DME) are increasing at an alarming rate, the available therapies are limited. Pharmaceuticals companies are only now beginning to develop therapeutics to treat back-of-the-eye conditions that are aggravating the financial, emotional, and physical burden on American society. Wet AMD - the most aggressive form of AMD and visual impairment - is attracting attention due to advances in therapeutic technology such as angiogenesis inhibitors, gene vaccines, and vascular endothelial growth factor (VEGF). The key challenge for wet AMD therapeutics is to demonstrate statistically significant benefits over existing treatments in all its sub segments. This is likely to garner reimbursement status from the Centers for Medicare & Medicaid Services (CMS) and enable the new pipeline biologic therapies to penetrate the market. This research looks at the competitive environment inherent in the AMD, DR, and DME markets. It covers disease etiology, patient forecast numbers, current therapeutic options, in-depth analysis of emerging therapies, revenue forecasts, and comparative product analysis. Innovative Angiogenesis Inhibitors in Late Stage Clinical Development Causing Excitement in Market The wet AMD therapeutic sector, by itself, is expected to be worth $1.84 billion in 2010. With many innovative angiogenesis inhibitors in late-stage clinical development with new drug applications (NDAs) soon to be filed, this segment is on the brink of a revolution whereby patients can gain access to vision-saving therapies. Improving on the conventional therapies currently in use, the new treatments are likely to not only prevent the progression of disease, but also cause the swollen blood vessels to regress - thereby restoring lost visual capabilities. CMS’ Change in Reimbursement Coverage Bodes Well For New Therapies Of the two major subtypes of wet AMD - predominantly classic and minimally classic or occult - available treatments were FDA-approved only for the predominantly classic subtype. However, a change in reimbursement coverage instituted by the CMS has expanded the reimbursement of Visudyne into occult and minimally classic subtypes with lesions smaller than four disc areas. The expansion of coverage is expected to be a key driver for new therapies entering the market. This is because many of their clinical results demonstrate greater therapeutic response in all subtypes of wet AMD regardless of lesion size, and therefore, are most likely to be able to obtain the highly sought after reimbursement status. Reimbursement is extremely important since all of the patients affected by AMD are over the age of 65, and therefore, qualify for Medicare coverage.
|
|
|||
|
About MarketResearch.com
|
||||